KMPH 5.55 (+0.91%)
US4884452065BiotechnologyBiotechnology

KemPharm (KMPH) Stock Highlights

5.55 | +0.91%
2023-04-04 00:38:27
KemPharm Inc is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of treatments for the central nervous system, CNS, and rare disease indications. The company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. Its LAT platform technology discovers and develops prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability, and safety. KemPharms two lead product candidates are KP415, and KP484, which are both based on a prodrug of d-methylphenidate, or d-MPH; KP879, is also based on a prodrug of d-MPH.

Statistics

Range Today
5.4 5.64
Volume Today 153.82K
Range 1 Year
4 6.92
Volume 1 Year 74.43M
Range 3 Year
1.936 22.08
Volume 3 Year 508.87M
Range 10 Year
1.936 418.4
Volume 10 Year 527.35M

Highlights

Market Capitalization 200.47M (small)
Floating Shares 31.26M
Current Price 5.55
Price To Earnings -6.41
Price To Revenue 13.28
Price To Book 2.14
Earnings Per Share -0.91
Payout Ratio 0%

Performance

Latest +0.91%
1 Month +2.78%
3 Months +22.52%
6 Months -11.48%
1 Year +7.35%
3 Years +73.44%
5 Years -94.7%
10 Years -97.05%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.